Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with radionuclides for selective treatment of cancers, which are unsuitable for surgery or external radiation; and Archaea Platin, aimed at delivering of chemotherapeutic substance cisplatin selectively to tumors in order to reduce side effects on healthy tissue. The Company's technology comprises a technology platform IonXgel, which is a nano-sized biocompatible material consisting of polar polymers; a protein-based drug delivery platform, ProtRc; and 3PEG, a platform which enables attachment of polyethylene glycol (PEG) derivatives to small molecules (PEGylation).